VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Fennec Pharmaceuticals Executive Compensation (FY25)

FENC · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Jeffrey Hackman
Latest say-on-pay support
=
June 10, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Fennec Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 10, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Fennec Pharmaceuticals brief$500Get the executive brief
Velarion Intel, one year, every company
182 figures on this page: 171 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jeffrey Hackman: $1,611,862 → $1,722,154 (6.8% higher)
Say-on-pay support: 88.4% → 98.3% (9.9 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Fennec Pharmaceuticals' chief executive and what were they paid?
Jeffrey Hackman was paid $1,722,154 in total compensation as Chief Executive Officer for fiscal 2025. Hackman's total moved 6.8% higher from the $1,611,862 reported for fiscal 2024.
What was Fennec Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 98.3% of votes cast for or against in favor at the meeting held June 10, 2026 for fiscal 2025.
Which companies are in Fennec Pharmaceuticals' peer group?
The disclosed peer group names AadiBioscience, Aldeyra Therapeutics, Anavex Life Sciences, BioXcel Therapeutics and Chimerix, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rostislav Raykov
CEO
◇◇—————◇
Robert Andrade
CFO
◇◇—————◇
Shubh Goel
CCO
◇——————◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rostislav Raykov
CEO
◇◇◇◇———◇
Adrian Haigh
COO
◇◇—◇———◇
Robert Andrade
CFO
◇◇◇◇———◇
Shubh Goel
CCO
————————
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Andrade
CFO
◇◇◇◇———◇
Jeffrey Hackman
Chief Executive Officer
◇——◇———◇
Pierre Sayad
Chief Medical Officer
◇——◇———◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Andrade
Chief Financial Officer
◇◇◇◇———◇
Jeffrey Hackman
Chief Executive Officer
◇◇◇◇———◇
Pierre Sayad
Chief Medical Officer
◇—◇————◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
BrugheraOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
IslamOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RallisOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
CookOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Dr. Khalid Islam
Board chair
◇—◇———◇
Mr. Rallis
◇—◇———◇
Mr. Chris A. Rallis
◇—◇———◇
Dr. Marco Brughera
◇—◇———◇
Dr. Jodi Cook
◇—◇———◇
Rosty Raykov served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
  • AadiBioscience symbol not shown
  • Aldeyra Therapeutics ALDX
  • Anavex Life Sciences AVXL
  • BioXcel Therapeutics BTAI
  • Chimerix CMRX
  • Geron GERN
  • MEI Pharma MEIP
  • Mersana Therapeutics MRSN
  • Palatin Technologies PTNT
  • SIGA Technologies SIGA
  • TRACON Pharmaceuticals TCON

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 10, 2026=◇◇◇
2024June 3, 2025=◇◇◇
2023June 25, 2024=◇◇◇
2022June 12, 2023=◇◇◇
2021June 14, 2022=◇◇◇
2020June 29, 2021=◇◇◇
2019June 22, 2020=◇◇◇
2018June 18, 2019=◇◇◇
2017June 7, 2018=◇◇◇
2016June 27, 2017=◇◇◇
2015June 8, 2016=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jeffrey Hackman (Chief Executive Officer), FY2025 total compensation $1,722,154 (base salary $586,343) [exec_comp, SEC accession 0001104659-26-050339, filed 2026-04-28]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Fennec Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Fennec Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Fennec Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Fennec Pharmaceuticals' disclosed peer group is defensible, who names Fennec Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
182 figures on this page: 171 cited to the filing that reported them, 11 calculated from figures it prints.
171 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001104659-26-072425
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-050339
  3. 0001104659-25-055992
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001104659-24-074748
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001558370-24-007979
  6. 0001104659-23-070486
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-22-071469
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001104659-21-087646
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001104659-20-076016
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001144204-19-031577
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001144204-18-033684
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001144204-17-034753
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001144204-16-107723
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Fennec Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/FENC (accessed 2026).
Short form: data: Velarion

The Fennec Pharmaceuticals brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Fennec Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Fennec Pharmaceuticals discloses

The companies named in FENC's own disclosed peer group.

Aldeyra TherapeuticsAnavex Life SciencesChimerixGeronMersana TherapeuticsSIGA Technologies

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy